H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

On May 28, Oren Livnat, an analyst from H.C. Wainwright initiated coverage of Trevi Therapeutics, Inc. (NASDAQ:TRVI) with a Buy rating and a $21 price target. The update comes after the company released additional analysis from the Phase 2a RIVER trial of Haduvio in patients with Refractory Chronic Cough.

The company released additional analysis from phase 2a RIVER trial suggesting a more de-risked path to approval as compared to the current market expectations, said the analyst. He believes that the company can achieve over $1 billion in revenue from the drug's treatment of refractory chronic cough alone. Moreover, the Idiopathic Pulmonary Fibrosis chronic cough could be another significant revenue stream for Trevi Therapeutics, Inc. (NASDAQ:TRVI).

The current market capitalization of the company is around $627 million which is undervalued considering the strong results from the RIVER trial, said the analyst. Livna expects Haduvio to become a best-in-class for both Idiopathic Pulmonary Fibrosis and refractory chronic cough.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, which is an investigational therapy aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.

While we acknowledge the potential of TRVI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TRVI and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.

Disclosure: None.